中国肺癌杂志2017，Vol.20Issue(3)：205-212,8.DOI:10.3779/j.issn.1009-3419.2017.03.10
天然中药单体及衍生物调控非小细胞肺癌自噬的研究新进展
Advances in the Research of the Regulation of Chinese Traditional Medicine Monomer and Its Derivatives on Autophagy in Non-small Cell Lung Cancer
摘要
Abstract
The high morbidity and mortality of non-small cell lung cancer (NSCLC) did influence the quality of life of tumor patients world-wide. There is an urgent need to develop new therapies that have high anti-tumor activity and low toxicity side effects. It is widely accepted that autophagy can play diverse roles in carcinogenesis, such as induces pro-death of lung cancer cells or helps the escape from cell death, making it become a proper anticancer target. It's believed that various monomers of Chinese traditional medicine closely correlates to anti-NSCLC activities, and that even could affect the acquired multiple drug resistance (MDR). Furthermore, autophagy might be the underling mechanisms which could play a role as the candidate targets of natural active compounds. Recent studies of terpenoids, alkaloid, dietary polyphenols, saponins and other active ingredients that extracted from a large variety of herbs suggest that different monomer compounds could either regulate the activity of pro-death autophagy or influence the level of protective autophagy of NSCLC cells, thus changing their drug sensitivity and cell viability. This paper aims to give a systemic description of the latest advances about natural compounds and their derivatives that involved in tumorigenesis of NSCLC via inducing the autophagy.关键词
肺肿瘤/中药提取物/自噬/耐药Key words
Lung neoplasms/Chinese herbal or plant extracts/Autophagy/Drug resistance引用本文复制引用
相美亦,李瑞蕾,张志伟,宋鑫..天然中药单体及衍生物调控非小细胞肺癌自噬的研究新进展[J].中国肺癌杂志,2017,20(3):205-212,8.基金项目
本文受国家自然科学基金(No.U1502222, No.81470005, No.81260307)、2013-2014年度国家临床重点专科建设项目(云南省肿瘤医院肿瘤科)、云南省科技厅应用基础研究项目(No.2015FB074, No.2014FB065, No.2014FB064)资助 This study was supported by the grants from the National Natural Science Foundation of China (to Xin SONG)(No.U1502222, No.81470005, No.81260307), the National Clinical Key Specialty Construction Projects of Oncology of the National Health and Family Planning Commission of China (to Xin SONG)(Awarded to the Tumor Hospital of Yunnan Province: 2013-2014), the Applied Basic Research Program of Yunnan Province (to Ruilei LI)(No.2015FB074, No.2014FB065, No.2014FB064). （No.U1502222, No.81470005, No.81260307）
